Vector VestAdvertisement SPDR Advertisement
Home > Boards > US Listed > Biotechs > Ariad Pharmaceuticals, Inc. (ARIA)

Buyout Rumors?-

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
bellweather1 Member Profile
Member Level 
Followed By 9
Posts 2,380
Boards Moderated 0
Alias Born 06/08/10
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 1/26/2015 4:10:55 PM
ARIAD Announces Appointment of Thomas J. DesRosier, Senior Pharmaceutical-Industry Counsel, as Chief Legal & Administrative O... "Business Wire" - 1/22/2015 7:35:00 AM
ARIAD meldet endgültige Entscheidung der Europäischen Kommission mit Bestätigung der Zulassung von Iclusig für die besteh... "Business Wire" - 1/20/2015 1:03:00 PM
ARIAD annonce la décision favorable finale de la Commission Européenne concernant les indications approuvées d'Iclusig en ... "Business Wire" - 1/20/2015 11:39:00 AM
ARIAD Announces Final Decision from European Commission Endorsing Iclusig’s Approved Indications Throughout Europe "Business Wire" - 1/20/2015 7:35:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 1/15/2015 4:31:11 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 1/14/2015 6:01:45 AM
ARIAD Announces Key Strategic Objectives for 2015 Expected to Lead Company to Profitability in Three Years "Business Wire" - 1/13/2015 7:35:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 1/7/2015 4:16:37 PM
ARIAD kündigt Start einer Phase-2-Dosisfindungsstudie zu Iclusig (Ponatinib) für Mitte 2015 an "Business Wire" - 1/6/2015 1:39:00 PM
ARIAD annonce le début de son essai de dosage de phase II d'Iclusig® (ponatinib) mi-2015 "Business Wire" - 1/6/2015 1:39:00 PM
ARIAD Announces Phase 2 Dose-Ranging Trial of Iclusig (Ponatinib) to Begin by Mid-2015 "Business Wire" - 1/6/2015 7:35:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 12/30/2014 4:18:58 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 12/30/2014 4:04:45 PM
ARIAD meldet Vermarktungsabkommen für Iclusig in sieben mittel- und osteuropäischen Ländern "Business Wire" - 12/30/2014 9:15:00 AM
ARIAD Announces Commercialization Agreement for Iclusig in Seven Central and Eastern European Countries "Business Wire" - 12/30/2014 7:35:00 AM
ARIAD annonce une entente de commercialisation pour l’Iclusig dans sept pays d’Europe centrale et de l’Est "Business Wire" - 12/30/2014 7:35:00 AM
ARIAD & Otsuka Announce Co-Development & Commercialization Agreement for Iclusig to Treat Leukemias in Japan & Nine Other Asi... "Business Wire" - 12/23/2014 7:00:00 AM
ARIAD To Present at The 33rd Annual J.P. Morgan Healthcare Conference "Business Wire" - 12/22/2014 7:35:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 12/19/2014 4:29:59 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 12/18/2014 4:10:03 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 12/11/2014 4:16:07 PM
ARIAD Announces Long-Term Safety & Efficacy Data of Ponatinib in Chronic-Phase Chronic Myeloid Leukemia from Phase 1 Clinical... "Business Wire" - 12/9/2014 7:35:00 AM
ARIAD Announces Follow-up Data from Phase 1 & PACE Trials of Ponatinib in Patients with T315I Mutation in Chronic Myeloid Leu... "Business Wire" - 12/9/2014 7:35:00 AM
ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial "Business Wire" - 12/8/2014 7:35:00 AM
bellweather1 Member Level  Wednesday, 10/19/11 01:37:42 PM
Re: bellweather1 post# 13354
Post # of 58913 
Buyout Rumors?-

Looks like we're running up in tandem with HGSI(+15.2%) and DNDN(+5.75%) today.

Yesterday's HGSI speculation may be driving us(in addition to the breakout) along with others viewed by some as attractive takeover candidates.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist